Emedgene
Germline variant interpretation software for genomic analysis
Software · Cloud SaaSCompany source
Company profile
About Emedgene
Emedgene is a genomic interpretation software platform that has been acquired by and integrated into Illumina's portfolio of genomics solutions. The company specializes in germline variant interpretation, providing AI-powered tools that help clinical laboratories, genetic counselors, and healthcare providers analyze and interpret genetic variants more efficiently. Emedgene's platform automates the complex process of variant classification, leveraging artificial intelligence and machine learning to accelerate the diagnosis of genetic and rare diseases. The software integrates with next-generation sequencing (NGS) workflows and supports clinical applications in reproductive health, oncology, and genetic disease diagnosis. As part of Illumina's Connected Analytics suite, Emedgene serves genetic testing laboratories, health systems, and research institutions seeking to streamline their genomic interpretation workflows. The platform is designed to reduce the time from sequencing to clinical reporting while maintaining high accuracy in variant classification, supporting the broader mission of making genomic medicine more accessible and actionable in clinical practice.
Company description Emedgene official website
Primary marketPrecision Medicine & Genomics
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Emedgene?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Genetic diseases
- Hereditary cancer syndromes
- Hereditary conditions
- Rare diseases
- Reproductive health conditions
Who it serves
- Clinical genomics labs
- Genetic counselors
- Genetic testing laboratories
- Health systems
- Research institutions
Deployment & integration
Cloud Saas deployment with recorded integration context.
Recorded integration context: DRAGEN Secondary Analysis, Illumina BaseSpace Sequence Hub, Illumina Connected Analytics, NGS sequencing platforms.
Geographic context
MarketsNot currently listed
Company sourceOfficial website
Company milestones
Platform expansion
Acquired by and integrated into Illumina's Connected Analytics portfolio as part of their genomics software suite
Partnerships
Recorded partners
- Illumina (parent company/acquirer)
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Cohort Expansion and Genotype-Phenotype Analysis of RAB11A-Associated Neurodevelopmental Disorder.Pediatric neurology · Nov 1, 2024
Evaluation of an automated genome interpretation model for rare disease routinely used in a clinical genetic laboratory.Genetics in medicine : official journal of the American College of Medical Genetics · Jun 1, 2023
Functional analysis of a novel de novo variant in PPP5C associated with microcephaly, seizures, and developmental delay.Molecular genetics and metabolism · May 1, 2022
Bi-allelic variants in IPO8 cause a connective tissue disorder associated with cardiovascular defects, skeletal abnormalities, and immune dysregulation.American journal of human genetics · Jun 3, 2021
Mutations in HOGA1 do Not Confer a Dominant Phenotype Manifesting as Kidney Stone Disease.The Journal of urology · May 1, 2021
Germline variant in REXO2 is a novel candidate gene in familial pheochromocytoma.Genetics research · May 1, 2020
Clinical validation
Clinical-trial records
The Belgian Genome Resource to Resolve Rare DiseasesNCT07051213 · Mentioned · COMPLETED
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Accelerated time to diagnosis
Automated variant interpretation reduces analysis time
Improved workflow efficiency
Streamlines genomic interpretation for clinical laboratories
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from Emedgene
Recent articles published on Emedgene's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Precision Medicine & Genomics
Companies using AI to analyze genomic, proteomic, metabolomic, or multi-omics data to provide personalized treatment recommendations, identify genetic risks, or develop targeted therapies. Includes genomic sequencing platforms with AI analysis, preventive medicine based on genetic risk assessment, and longevity care based on molecular and genetic data.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.